Loading...
•
Mar 31, 2023
CRISPR Therapeutics Q1 2023 Earnings Report
CRISPR Therapeutics experienced strong portfolio momentum and completed regulatory submissions for exa-cel.
Key Takeaways
CRISPR Therapeutics reported financial results for the first quarter ended March 31, 2023. The company continued to advance its portfolio programs, including regulatory submissions for exa-cel and initiation of clinical trials for next-generation CAR T candidates.
Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD).
EU and U.K. submissions validated by European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA).
Enrollment and dosing ongoing for CTX110, targeting CD19+ B-cell malignancies, and CTX130, targeting CD70 for the treatment of T cell lymphomas.
Initiated clinical trials for next-generation CAR T candidates, CTX112 targeting CD19+ B-cell malignancies and CTX131, targeting CD70+ solid tumors.
CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
CRISPR Therapeutics expects to move multiple programs utilizing in vivo approaches into the clinic within the next 12 months and continues to advance CTX310 into clinical trials this year.
Positive Outlook
- Ongoing progress with in vivo approaches for liver gene editing.
- Advancing CTX310, targeting ANGPTL3, into clinical trials this year.
- Potential for exa-cel to become the first approved CRISPR-based therapy.
- Advancing next-generation CAR T candidates, CTX112 and CTX131, into clinical trials.
- Collaboration with Vertex and ViaCyte for therapeutic products in the diabetes field.